Company Filing History:
Years Active: 2004
Title: Innovations in Cancer Treatment by Anders Olsson
Introduction
Anders Olsson is a notable inventor based in Dalby, Sweden. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. His work focuses on the use of specific compounds to enhance the effectiveness of cancer therapies.
Latest Patents
Anders Olsson holds a patent titled "Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells." This patent describes methods for killing tumor or cancer cells in human patients using aryl N-substituted carboxamides. These compounds may include N-substituted nicotinamide or N-substituted benzamide, which can be utilized directly as chemotherapeutic agents or as sensitizers for radiation or other chemotherapeutic agents. The patent also introduces new compositions for such use, including N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide and N-(2-diethylamino-ethyl) nicotinamide, along with their acid addition salts, such as hydrochlorides. He has 1 patent to his name.
Career Highlights
Anders Olsson is associated with Oxigene, Inc., a company dedicated to developing innovative cancer therapies. His work has been instrumental in advancing the understanding and treatment of cancer, particularly through the application of his patented compounds.
Collaborations
Anders has collaborated with notable colleagues, including Ronald W Pero and Tomas Ekberg. Their combined expertise has contributed to the development of effective cancer treatment strategies.
Conclusion
Anders Olsson's innovative work in cancer treatment through his patented inventions highlights the potential of aryl N-substituted carboxamides in enhancing therapeutic outcomes. His contributions continue to pave the way for advancements in oncology.